ARTICLE | Management Tracks
Plus: Tanya Wallace to head of neuroscience and ophthalmology at AbbVie, and updates from Editas and Zentalis
By Jeff Cranmer, Executive Editor, and Gunjan Ohri, Data Content Analyst
December 14, 2024 2:12 AM UTC
Gilead Sciences Inc. (NASDAQ:GILD) has found its successor to Merdad Parsey as CMO in Dietmar Berger, the former CMO and global head of development at Sanofi (Euronext:SAN; NASDAQ:SNY). Berger has held senior roles at three other large biopharmas: Amgen Inc. (NASDAQ:AMGN), Bayer AG (Xetra:BAYN) and Genentech Inc.
Tanya Wallace has left Neumora Therapeutics Inc. (NASDAQ:NMRA) for AbbVie Inc. (NYSE:ABBV), where she is now VP, head of neuroscience and ophthalmology discovery research…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654477/gilead-hires-dietmar-berger-as-cmo